T he secretion of certain types of cytokines from tumors can activate immunocompetent cells, and antitumor effects have been observed in the inoculated host animals. 1 Cytokines released from T-helper type-1 cells but not type-2 cells have more effectively produced antitumor activities in a number of experimental animal models because the cytokines enhance cell-mediated immunity.
1,2 IL-21, a novel cytokine, has homologous structure to IL-2, IL-4 and IL-15, with relatively restricted expression in activated peripheral CD4 + T cells. 3 The expression of the IL-21 receptor is also restricted to lymphohematopoietic tissues, particularly in activated T, B and NK cells. 3, 4 IL-21 can provide signals for the proliferation of activated peripheral T cells and the proliferation/maturation of NK cells. 3 Moreover, IL-21 enhances the lytic function of NK cells. 3 A recent study of mice lacking the IL-21 receptor demonstrated that IL-21 enhanced interferon (IFN)-g production and cytotoxic function of activated T cells. 5 We therefore examined the generation of antitumor responses by inoculating murine colon carcinoma (Colon 26) cells transduced with the IL-21 gene into syngeneic and T-cell-defective nude mice.
Materials and methods

Cells and mice
BALB/c and BALB/c nu/nu mice (5 to 6-week-old females) were purchased from Nippon Clea (Tokyo, Japan). Colon 26, a carcinogen-induced undifferentiated adenocarcinoma cell line, 6 and RL male-1, an irradiationinduced lymphoma line of BALB/c origin, 7 were provided by Dr J Hamuro (Ajinomoto, Tokyo, Japan) and Dr T Ebina (Miyagi Cancer Center, Natori, Japan), respectively. Both ecotropic c2 and amphotropic PA317 packaging cells were obtained from the American Type Culture Collection (Manassas, VA, USA). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.
Isolation of murine IL-21 cDNA
The reverse transcription-based polymerase chain reaction method was used to clone murine IL-21 cDNA. Poly (A) + mRNA was extracted from Colon 26 tumors developed in BALB/c mice, and synthesized first-strand cDNAs were amplified with two primers: 5 0 -AT-TAAAGCTTCTGGTGGCATGGAGAGGAC-3 0 (as a 5 0 primer) and 5 0 -TAGGATCCTGTGTTCTAGGAGA-GATGCTG-3 0 (as a 3 0 primer). Amplification was performed according to the manufacturer's recommendation (Perkin-Elmer Cetus, Norwalk, CT, USA) and it consisted of 30 cycles under the following condition: 30 s at 941C for denaturation, 30 s at 581C for primer annealing, and 30 s at 721C for primer extension. The sequence of the product was confirmed to be identical to the published sequence. 3 
Transduction of tumor cells
The retrovirus vector LXSN (provided by Dr AD Miller, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) 8 was used to harbor cloned IL-21 cDNA. The vector DNA with IL-21 cDNA was transfected into ecotropic c2 cells using lipofectin reagent (Life Technologies, Gaithersburg, MD, USA) and after the drug selection with G418 (600 mg/ml, Life Technologies), cellfree supernatants of G418-resistant clones were used as a retrovirus stock. The culture supernatants containing retrovirus were incubated with amphotropic PA317 cells in the presence of 8 mg/ml polybrene (Aldrich, Milwaukee, WI) for infection. Among the G418-resistant PA317 cells, a clone that produced the largest amount of IL-21 mRNA was selected and the culture supernatants were used for infecting Colon 26 cells. G418 (600 mg/ml)-resistant Colon 26 cells were cloned and used for experiments. As a control, G418-resistant Colon 26 cells that were retrovirally transduced with LXSN vector were also used.
Northern blot analysis
RNA (20 mg) was subjected to electrophoresis on a formaldehyde-agarose gel and transferred to a nylon filter. The filter was hybridized with [a-32 P]dCTP-labeled mouse IL-21 cDNA in a QuickHib solution (Stratagene, La Jolla, CA) with 0.1 mg/ml salmon sperm DNA at 681C for 1 h, and then washed with a solution of 0.2 Â SSC/ 0.1%SDS several times at 651C. The filter was rehybridized with a mouse elongation factor 1-a (EF-1 a) cDNA as a control. 
Animal experiments
Cells were injected intraperitoneally or subcutaneously into the right flank of naive BALB/c, BALB/c nu/nu or immunized BALB/c mice that received 20-Gy-irradiated cells. To deplete NK cells in vivo, mice were injected intraperitoneally with anti-asialo GM 1 antibody (50 mg/mouse, Wako, Osaka, Japan) 1 day before and 4 days after the inoculation of tumor cells. 9, 10 Tumor volume was calculated according to the formula 1/2 Â length Â width 2 , and statistical analysis was performed by one-way analysis of variance (ANOVA).
Production of IFN-g
Spleen cells from the mice (1 Â 10 7 /ml) that had rejected IL-21 producers (21 days after tumor inoculation) and those from the mice bearing either parent tumors or IL-21 producers (5 days after tumor inoculation) were cultured with 50-Gy-irradiated tumor cells (1 Â 10 6 /ml) in RPMI 1640 medium containing 10% fetal calf serum. Cell-free supernatants collected after 12 h were examined for the concentrations of IFN-g with an enzyme-linked immunosorbent assay (Biosource, Camarillo, CA, USA). Spleen cells from naive mice were used as a control. 
Cytotoxic assay
Results
Establishment of IL-21-expressing cells
Colon 26 cells were retrovirally transduced with the mouse IL-21 gene, and G418-resistant clones were subjected to Northern blot analysis. Among 22 clones, we selected two clones (Colon 26/IL-21#4 and #13) that produced large amounts of IL-21 transcript (Fig 1a) . Since antibody against IL-21 is currently unavailable, we could not show the amounts of IL-21 produced from the tumor cells. Expression levels of the class I molecules of the major histocompatibility complexes (H-2K d and H-2D d ) were moderately decreased in both IL-21-expressing clones compared with parent cells (Fig 1b) . The proliferation rate in vitro of both clones was not different from that of parent cells (data not shown). (Fig 2a) . In contrast, tumors derived from parent or vector DNA-transduced Colon 26 cells grew progressively. The mice that had rejected IL-21-producing clones became resistant to Colon 26 cells that were subsequently inoculated, but about a half of them developed irrelevant RL male-1 tumors (Table 1) . When the mice were treated with anti-asialo GM 1 ), a half of the mice rejected the mixed tumor cells after forming small tumor masses (Table 1 ). All the mice that received 5 Â 10 5 parent cells as a control developed tumors progressively. Mice immunized with irradiated Colon 26/IL-21#13 cells were also resistant to parent but not to RL male-1 cells that were subsequently inoculated (Table 1) , whereas immunization of mice with irradiated parent cells failed to induce systemic immunity (data not shown).
Antitumor effects in vivo
When nude mice were subcutaneously injected with Colon 26/IL-21#13 cells, they developed tumors, but the growth was retarded compared with that of parent tumors (Po0.05 on day 21) (Fig 2b) . When NK cells were depleted with anti-asialo GM 1 antibody, the growth of Colon 26/IL-21#13 tumors was not different from that of parent tumors (Fig 2c) .
Production of IFN-g and cytotoxic assay
We examined the production of IFN-g from spleen cells of the mice that had rejected Colon 26/IL-21#13 ( Table 2 ).
The spleen cells cultured with irradiated Colon 26 cells secreted larger amounts of IFN-g than those stimulated with irradiated RL male-1 cells. The cells, cultured without any stimulators, produced few amounts of IFNg as well as spleen cells from naive mice. Spleen cells from the mice bearing Colon 26/IL-21#13 tumors produced larger amounts of IFN-g than those from parent-tumorbearing mice, when they were stimulated with Colon 26 but not RL male-1 cells.
We examined cytotoxic activities of spleen cells from the mice that had rejected Colon 26/IL-21#13 cells (Fig 3a) . The spleen cells showed increased lytic activity to Colon 26 cells compared with naive spleen cells (Po0.05), and the cytotoxic activity to Colon 26 was stronger than that to irrevelant RL male-1 cells (Po0.05). These data showed that cytotoxic T cells were induced by the rejection of Colon 26/IL-21#13 cells. Spleen cells of the mice bearing Colon 26 or Colon 26/IL-21#13 tumors were also assayed for their cytotoxic activities to YAC-1 NK target cells (Fig 3c) . The cytotoxic activity obtained from Colon 26/IL-21#13-tumor-bearing mice was greater than that from parent-tumor-bearing mice (Po0.01) and from naive mice (Po0.01). Since the lytic activity of parent-tumor-bearing mice was not different from that of naive mice, inoculation of Colon 26/IL-21#13 cells increased NK activity in the mice. 
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Discussion
The present study showed for the first time that a novel cytokine IL-21 produced antitumor effects in vivo.
Immunocompetent mice rejected IL-21-producing tumors and subsequently generated protective immunity. The antitumor effects were influenced by the amounts of IL-21, because a half of the mice that were inoculated with IL-21 promotes the growth of T, B and NK cells in vitro, 3 and this IL-21-mediated stimulation is relatively stage-specific. IL-21 does not augment the proliferation of peripheral T cells unless they receive signals through Tcell receptors.
3 IL-21 may therefore increase systemic immune responses that have already been started. Initial activation of T and NK cells could be performed through their migration into the tumors and nonspecific inflammatory reactions. A recent study using IL-21-receptordeficient mice showed that IL-21 enhanced cytotoxic activity of NK cells but did not support their survival, and suggested that IL-21 mediates the transitional process from NK-cell-dominant innate immunity to T-cell-governing adaptive immunity. 5 The present data demonstrated the involvement of T and NK cells in the IL-21-mediated antitumor effects, but could not reveal their specific role in the linkage in vivo between innate and adaptive immunity.
The IL-21 receptor uses the common cytokine receptor g chain g c and has significant homology to the b chain of the IL-2 receptor and the a chains of the IL-4 and the IL-9 receptor. 11, 12 Although the IL-21-mediated signal processes involved the activation of JAK1, JAK3, STAT1 and STAT3, 12 the biological roles in vivo of IL-21 need to be further elucidated. In summary, transfer of the IL-21 gene into tumors can generate systemic immune responses against the tumors, and consequently is a possible therapeutic strategy for cancer treatment.
